Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

PRINCETON, N.J., Sept. 3 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Global Investor Healthcare Conference. Dr. Schaber is scheduled to present at 4:55 PM on Thursday, September 10, 2009 in the Spellman Salon of the New York Palace Hotel, New York. The presentation will be webcast live and may be accessed by visiting http://www.wsw.com/webcast/rrshq15/dorb.ob.

Dr. Schaber will provide updates on DOR's pipeline, including its lead product candidate orBec(R) which is soon to begin a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

A replay of Dr. Schaber's webcast will be available on DOR BioPharma's new website (www.dorbiopharma.com) for approximately 30 days following the presentation.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clin
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , ... August 31, 2015 , ... ... the world's most successful food and beverage processors, equipment manufacturers and leaders in ... product inspection and industrial weighing and formulation for manufacturers of bakery and snacks; ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, ... customer service. Images such as the Fonz in a lab coat and Large Marge ... the humdrum spectroscopy field. , FireflySci is proud to be the only cuvette ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
Breaking Biology Technology:METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... JLL Partners, a leading private equity investment fund ("JLL") ... JLL PharmaNet Holdings, LLC ("Parent"), through its wholly-owned subsidiary, ... affiliate of JLL, has commenced a tender offer for ... ) at a price of $5.00 per share net ...
... Calif., Feb. 12 BioMarin Pharmaceutical,Inc. (Nasdaq: ... first interim efficacy,analysis (IEA) for the Riquent(R) Phase ... determined that the continuation of the trial is,futile. ... decided to stop the,study, unblind the data and ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... on bringing the life saving potential of stem cells ... that between January 1, 2009, and today, it has ... Company previously said in press releases and CEO interviews ...
Cached Biology Technology:An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 2An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 3An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 4An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 5An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 6An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 7Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... An organelle called the nucleolus resides deep within the ... critical functions: it manufactures ribosomes, the molecular machines that ... proteins that do the work of life. , ... Sciences Division of the Department of Energy's Lawrence Berkeley ...
... A solar-powered robot with 20/20 vision, on a search-and-destroy quest ... crop rows at the experimental fields at the University of ... weeds while significantly reducing herbicide use. , The robot uses ... on a frame on top of the machine to give ...
... Women infected with dormant toxoplasmosis are more likely to ... negative, according to research by S. Kankova and colleagues ... University; the Centre of Reproductive Medicine; and GynCentrum, in ... of the parasite Toxoplasma gondii in the mothers' blood, ...
Cached Biology News:Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3Bad blood between boys and girls 2